NexMed Announces Presentation of Data at the 66th Annual Meeting of the American Academy of Dermatology

EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on its proprietary NexACT® drug delivery technology, today announced the presentation of data on NM100060, a topical onychomycosis (nail fungus) investigative drug product, at the 66^th Annual Meeting of the American Academy of Dermatology (AAD), in San Antonio from February 1-5, 2008. The presentation is being sponsored by Novartis Pharma AG and NexMed.

“Terbinafine HCI Nail Solution with and without Nail Penetration Enhancer: Evaluation of Minimum Inhibitory Concentration and Minimum Fungicidal Concentrations”

The presentation entitled, “Terbinafine HCI Nail Solution with and without Nail Penetration Enhancer: Evaluation of Minimum Inhibitory Concentration and Minimum Fungicidal Concentrations,” will take place on Monday, February 4, 2008 at 7:55am Central Time in the Henry B. Gonzalez Convention Center. A copy of the poster presentation is available from NexMed.

NM100060 is a topical application of Lamisil^® (terbinafine hydrochloride), formulated with terbinafine and NexMed’s patented NexACT permeation enhancer, and it is being developed to treat onychomycosis. NexMed entered into an exclusive, worldwide agreement with Novartis in September 2005, under which Novartis assumed all clinical development, regulatory, manufacturing and commercialization responsibilities for NM100060.

About NexMed

NexMed, Inc. is leveraging its proprietary NexACT drug delivery technology to develop innovative topical pharmaceutical products that address unmet medical needs. NM100060, a novel onychomycosis treatment exclusively licensed to Novartis, is currently in pivotal Phase 3 trials in the U.S. and Europe. In November 2007, NexMed’s New Drug Application for its alprostadil treatment for erectile dysfunction was accepted for review by the FDA and the Company signed a U.S. licensing agreement for the product with Warner Chilcott. NexMed's pipeline also includes a Phase 2 treatment for female sexual arousal disorder and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.